3/14
08:22 am
dyn
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data [Yahoo! Finance]
Low
Report
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data [Yahoo! Finance]
3/13
03:04 pm
dyn
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs [Yahoo! Finance]
Low
Report
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs [Yahoo! Finance]
3/10
09:52 pm
dyn
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade [Yahoo! Finance]
Low
Report
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade [Yahoo! Finance]
3/9
03:38 pm
dyn
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]
3/9
02:46 pm
dyn
Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
Low
Report
Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
3/9
01:41 pm
dyn
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case [Seeking Alpha]
Low
Report
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case [Seeking Alpha]
3/9
11:05 am
dyn
Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/8
06:13 pm
dyn
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) [Yahoo! Finance]
High
Report
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) [Yahoo! Finance]
3/8
06:13 pm
dyn
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) [Yahoo! Finance]
High
Report
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) [Yahoo! Finance]
3/8
06:01 pm
dyn
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
High
Report
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
3/8
06:00 pm
dyn
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
High
Report
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
3/3
08:03 am
dyn
Dyne Therapeutics (DYN) had its price target lowered by HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Dyne Therapeutics (DYN) had its price target lowered by HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
3/2
10:01 pm
dyn
Dyne Therapeutics (DYN) was given a new $38.00 price target by Chardan Capital.
Medium
Report
Dyne Therapeutics (DYN) was given a new $38.00 price target by Chardan Capital.
3/2
01:20 pm
dyn
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
Low
Report
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
3/2
01:05 pm
dyn
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
3/2
07:42 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/2
07:30 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2/25
08:03 am
dyn
Dyne Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Dyne Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
07:30 am
dyn
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Dyne Therapeutics to Participate in Upcoming Investor Conferences
2/22
04:00 pm
dyn
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Medium
Report
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
2/16
12:38 pm
dyn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry [Yahoo! Finance]
Low
Report
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry [Yahoo! Finance]
2/2
09:17 am
dyn
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
Medium
Report
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
1/27
04:12 am
dyn
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
Low
Report
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
1/20
10:24 am
dyn
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
Low
Report
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
1/20
07:30 am
dyn
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Low
Report
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1